DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced today that its stockholders re-elected Reuven Avital and David C. Bupp as Directors of the Company for terms ending at the 2010 Annual Meeting. David Bupp, Neoprobe’s President and CEO, provided the stockholders at the Company’s 2007 Annual Meeting with a business update. During his presentation, which followed the formal portion of the meeting, Mr. Bupp reviewed the Company’s activities over the past year highlighting the following milestones:
